Skip to content
lifestyle.childcarepartnerships.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Kyverna Therapeutics, Inc.
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
April 20, 2026
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
April 9, 2026
←
Previous Page
1
2